Jubilant Pharmova Ltd
NSE:JUBLPHARMA

Watchlist Manager
Jubilant Pharmova Ltd Logo
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Watchlist
Price: 1 097.4 INR 2.75%
Market Cap: 174.8B INR
Have any thoughts about
Jubilant Pharmova Ltd?
Write Note

Jubilant Pharmova Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jubilant Pharmova Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Accounts Receivables
â‚ą8B
CAGR 3-Years
-3%
CAGR 5-Years
-6%
CAGR 10-Years
1%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Accounts Receivables
â‚ą84.4B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Accounts Receivables
â‚ą55.9B
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
13%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Accounts Receivables
â‚ą129.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
14%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Accounts Receivables
â‚ą17.8B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
4%
M
Mankind Pharma Ltd
NSE:MANKIND
Accounts Receivables
â‚ą8.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jubilant Pharmova Ltd
Glance View

Market Cap
173.8B INR
Industry
Pharmaceuticals

Once rooted as a modest family business, Jubilant Pharmova Ltd. has evolved into a global powerhouse in the pharmaceutical and life sciences industry. Founded by the visionary Bhartia family, the company has sprawled across continents, transforming healthcare landscapes with its robust product portfolio. Jubilant Pharmova's journey is one painted with strategic diversification, cleverly balancing risk and driving sustainable growth. At its core, the company operates through three primary segments: Pharmaceuticals, Contract Research and Development Services, and Proprietary Drug Discovery. Each arm serves as a critical piece in the company's strategic mosaic, enhancing its resilience amid the ever-fluctuating pharmaceutical market dynamics. Underpinning Jubilant Pharmova's business model is its Pharmaceuticals segment, which churns a significant portion of its revenue. The company manufactures and sells an array of pharmaceutical products, including generics and specialty pharmaceuticals, which cater to multiple therapeutic areas. Further driving its financial engine is the Contract Research and Development Service segment, which offers outsourced R&D solutions to a host of pharmaceutical majors—a sector that has witnessed burgeoning demand alongside escalating R&D costs globally. On the innovation frontier, the Proprietary Drug Discovery segment embarks on uncharted territories, seeking novel drugs and solutions, paving the path for the future. Such a diversified approach not only positions Jubilant Pharmova as a formidable entity in the pharmaceutical domain but also provides a cushion against industry-specific headwinds, reinforcing its long-term sustainability.

JUBLPHARMA Intrinsic Value
903.88 INR
Overvaluation 18%
Intrinsic Value
Price

See Also

What is Jubilant Pharmova Ltd's Accounts Receivables?
Accounts Receivables
8B INR

Based on the financial report for Sep 30, 2024, Jubilant Pharmova Ltd's Accounts Receivables amounts to 8B INR.

What is Jubilant Pharmova Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
1%

Over the last year, the Accounts Receivables growth was -12%. The average annual Accounts Receivables growth rates for Jubilant Pharmova Ltd have been -3% over the past three years , -6% over the past five years , and 1% over the past ten years .

Back to Top